共 50 条
Annexin A1 Is a Physiological Modulator of Neutrophil Maturation and Recirculation Acting on the CXCR4/CXCL12 Pathway
被引:26
|作者:
Machado, Isabel Daufenback
[1
]
Spatti, Marina
[1
]
Hastreiter, Araceli
[1
]
Santin, Jose Roberto
[1
]
Fock, Ricardo Ambrosio
[1
]
Gil, Cristiane Damas
[2
]
Oliani, Sonia Maria
[3
]
Perretti, Mauro
[4
]
Poliselli Farsky, Sandra Helena
[1
]
机构:
[1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, SP, Brazil
[2] Fed Univ Sao Paulo UNIFESP, Dept Morphol & Genet, Sao Paulo, SP, Brazil
[3] Sao Paulo State Univ UNESP, Inst Biociencias Letras & Ciencias Exatas IBILCE, Dept Biol, Sao Paulo, Brazil
[4] Queen Mary Univ London, Barts & London Sch Med, William Harvey Res Inst, Ctr Biochem Pharmacol, London, England
基金:
英国惠康基金;
巴西圣保罗研究基金会;
关键词:
MESENCHYMAL STEM-CELLS;
BONE-MARROW;
IN-VIVO;
BLOOD;
MOBILIZATION;
GLUCOCORTICOIDS;
DIFFERENTIATION;
CLEARANCE;
CXCR4;
IDENTIFICATION;
D O I:
10.1002/jcp.25346
中图分类号:
Q2 [细胞生物学];
学科分类号:
071009 ;
090102 ;
摘要:
Neutrophil production and traffic in the body compartments is finely controlled, and the strong evidences support the role of CXCL12/CXCR4 pathway on neutrophil trafficking to and from the bone marrow (BM). We recently showed that the glucocorticoid-regulated protein, Annexin A1 (AnxA1) modulates neutrophil homeostasis and here we address the effects of AnxA1 on steady-state neutrophil maturation and trafficking. For this purpose, AnxA1(-/-) and Balb/C wild-type mice (WT) were donors of BM granulocytes and mesenchymal stem cells and blood neutrophils. In vivo treatments with the pharmacological AnxA1 mimetic peptide (Ac2-26) or the formyl peptide receptor (FPR) antagonist (Boc-2) were used to elucidate the pathway of AnxA1 action, and with the cytosolic glucocorticoid antagonist receptor RU 38486. Accelerated maturation of BM granulocytes was detected in AnxA1(-/-) and Boc2-treated WT mice, and was reversed by treatment with Ac2-26 in AnxA1(-/-) mice. AnxA1 and FPR2 were constitutively expressed in bone marrow granulocytes, and their expressions were reduced by treatment with RU38486. Higher numbers of CXCR4(+) neutrophils were detected in the circulation of AnxA1(-/-) or Boc2-treated WT mice, and values were rescued in Ac2-26-treated AnxA1(-/-) mice. Although circulating neutrophils of AnxA1(-/-) animals were CXCR4(+), they presented reduced CXCL12-induced chemotaxis. Moreover, levels of CXCL12 were reduced in the bone marrow perfusate and in the mesenchymal stem cell supernatant from AnxA1(-/-) mice, and in vivo and in vitro CXCL12 expression was re-established after Ac2-26 treatment. Collectively, these data highlight AnxA1 as a novel determinant of neutrophil maturation and the mechanisms behind blood neutrophil homing to BM via the CXCL12/CXCR4 pathway. (C) 2016 Wiley Periodicals, Inc.
引用
收藏
页码:2418 / 2427
页数:10
相关论文